Eingun James Song, MD, reviews the risks of under-treating pediatric atopic dermatitis and post hoc growth data with dupilumab.

A high-risk molecular result can change management in thin and node-negative melanoma. Dr. Singh explains how GEP findings shape sentinel node biopsy, imaging, and surveillance decisions.

Phase 2/3 data show sustained hair growth and favorable safety outcomes with oral VDPHL01 in men with androgenetic alopecia.

A patient describes losing most of her hair in a single shower, then being told it was stress. Her account shows how dismissal delays diagnosis and treatment of an autoimmune disease.

Cost and insurance coverage, not efficacy alone, ultimately determined this patient's treatment course. His account of near ...

Mark Lebwohl, MD, reviews the safety, dosing, and efficacy of oral TYK2 inhibitors and icotrokinra in psoriasis.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active ...

Jessica Scales, PhD, of the Melanoma Research Alliance, reviewed clinical trial access and clinician involvement in the RARE ...

Dermatology Times is looking back on the top stories in dermatology from the month of October. From major data presented at ...

A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve ...

Mark Lebwohl, MD, describes his approach on when to start systemic therapy, access considerations, and dupilumab safety and ...

Two oral trial drugs changed one patient's daily life, culminating in his first beach visit without protective gear. He and ...